XML 50 R16.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Stock- based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2012
Stock-based Compensation [Abstract] |
Stock-based Compensation | (9) Stock-based Compensation Stock Plans The Company’s equity incentive plan was amended, as approved by stockholders on June 25, 2009, to (i) change the name of the plan from the Amended and Restated Nuvelo, Inc. 2004 Equity Incentive Plan to the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan, or the Equity Plan, (ii) increase the maximum number of shares issuable under the plan, revise the formula for determining the maximum number of shares issuable under the plan and implement new share usage rules; and (iii) adjust the award limitations for stock options and stock appreciation rights. As a result of such amendment, the maximum number of shares issuable under the Equity Plan was increased by 54,387 shares. The Equity Plan provides for the granting of stock options (including indexed options), stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December 31, 2012, options to purchase 67,630 shares were outstanding under the Equity Plan, and 80,255 shares were reserved for future awards. In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of three to four years from the date of grant and have a maximum term of ten years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date. ARCA’s other stock plans under which options remained outstanding as of December 31, 2012 are the Non-Employee Director Stock Option Plan. As of December 31, 2012, options to purchase 83 shares were outstanding under this stock plan. In conjunction with the Merger, the Company discontinued grants under its 2004 Stock Option Plan effective January 27, 2009. As of December 31, 2012, options to purchase 76,305 shares with a weighted average exercise price of $14.04 per share were outstanding under this plan. Options and awards outstanding under this plan will continue to vest according to the original terms of each grant. No new awards will be granted under this plan. Subsequent to the Merger, the Company has granted stock-based compensation awards under the Equity Plan. The Company granted options to purchase 5,833 and 27,450 shares of common stock in the years ended December 31, 2012 and 2011, respectively. The fair values of employee stock options granted in the years ended December 31, 2012 and 2011 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:
|  | Years Ended December 31, |
|  | 2012 |  |  | 2011 |
Expected term |  |  | 5.3 years |  |  |  | 5.8 years |
Expected volatility |  |  | 108 | % |  |  | 110 | %
Risk-free interest rate |  |  | 0.15 | % |  |  | 2.20 | %
Expected dividend yield |  |  | 0 | % |  |  | 0 | %
Weighted-average grant date fair value per share |  | $ | 4.68 |  |  | $ | 10.95 |
A summary of ARCA’s stock option activities for the years ended December 31, 2012 and 2011, and related information as of December 31, 2012, is as follows:
|  | For the years ended December 31, |
|  | 2012 |  |  | 2011 |
|  | # of Options |  |  | Weighted Average Exercise Price |  |  | # of Options |  |  | Weighted Average Exercise Price |
Options outstanding, beginning of period |  |  | 144,039 |  |  | $ | 19.20 |  |  |  | 158,873 |  |  | $ | 191.22 |
Granted |  |  | 5,833 |  |  |  | 6.00 |  |  |  | 27,450 |  |  |  | 13.44 |
Exercised |  |  | — |  |  |  | 0.00 |  |  |  | (188 | ) |  |  | 7.86 |
Forfeited and cancelled |  |  | (5,853 | ) |  |  | 27.96 |  |  |  | (42,096 | ) |  |  | 664.86 |
Options outstanding, end of period |  |  | 144,019 |  |  | $ | 18.28 |  |  |  | 144,039 |  |  | $ | 19.20 |
Options exercisable, end of period |  |  | 125,666 |  |  | $ | 18.77 |  |  |  | 102,691 |  |  | $ | 20.10 |
Options vested and expected to vest |  |  | 142,227 |  |  | $ | 18.30 |  |  |  |  |  |  |  |  |
The total intrinsic value of options exercised for the years ended December 31, 2012 and 2011 was $0 and $1,000, respectively. As of December 31, 2012, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $150,000 which is expected to be recognized over a weighted average period of 0.9 years. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures. The following table summarizes information about stock options outstanding and exercisable as of December 31, 2012:
|  |  |  |  |  |  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Term (in years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  |  | Weighted Average Exercise Price |
$0.36 |  | — |  | $ | 3.60 |  |  |  | 1,248 |  |  |  | 2.42 |  |  | $ | 3.13 |  |  |  | 1,248 |  |  | $ | 3.13 |
5.40 |  | — |  |  | 5.40 |  |  |  | 33,844 |  |  |  | 1.20 |  |  |  | 5.40 |  |  |  | 33,844 |  |  |  | 5.40 |
6.00 |  | — |  |  | 11.16 |  |  |  | 22,078 |  |  |  | 5.19 |  |  |  | 9.73 |  |  |  | 21,883 |  |  |  | 9.76 |
13.44 |  | — |  |  | 13.44 |  |  |  | 25,363 |  |  |  | 7.87 |  |  |  | 13.44 |  |  |  | 14,115 |  |  |  | 13.44 |
16.14 |  | — |  |  | 17.40 |  |  |  | 26,354 |  |  |  | 5.91 |  |  |  | 16.96 |  |  |  | 20,386 |  |  |  | 17.09 |
17.82 |  | — |  |  | 33.42 |  |  |  | 34,570 |  |  |  | 5.55 |  |  |  | 27.85 |  |  |  | 33,628 |  |  |  | 27.95 |
87.47 |  | — |  |  | 1,908.00 |  |  |  | 562 |  |  |  | 3.43 |  |  |  | 856.14 |  |  |  | 562 |  |  |  | 856.14 |
|  |  |  |  |  |  |  |  | 144,019 |  |  |  | 4.91 |  |  | $ | 18.28 |  |  |  | 125,666 |  |  | $ | 18.77 |
For the years ended December 31, 2012 and 2011 and for the period from Inception through December 31, 2012, the Company recognized the following non-cash, share-based compensation expense (in thousands):
|  | Years Ended December 31, |  |  | Period from December 17, 2001 (date of inception) to December 31, 2012 |
|  | 2012 |  |  | 2011 |  |
Research and Development |  | $ | 94 |  |  | $ | 117 |  |  | $ | 590 |
Selling, General and Administrative |  |  | 212 |  |  |  | 191 |  |  |  | 1,611 |
Restructuring Expense |  |  | — |  |  |  | — |  |  |  | 387 |
Total |  | $ | 306 |  |  | $ | 308 |  |  | $ | 2,588 |
Stock-based compensation expense related to non-employees was negligible in 2012 and 2011. ARCA did not recognize any tax benefit related to employee stock-based compensation cost as a result of the full valuation allowance on its net deferred tax assets.

X
- Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 93-6 -Paragraph 53 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64, 65, A240 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration